MetaCap

AtriCure Inc. (ATRC)

NASDAQ: ATRCHealth CareMedical/Dental InstrumentsUSD

55.39+1.28 (+2.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ATRC stock chart

Technical analysis

Key statistics

All statistics
P/E (TTM)
178.68
52-week range
25.36 – 66.02
Day range
54.03 – 56.14
Volume / Avg
813.08K / 1.04M
Beta
—

52-week range

$25.36$66.02

ATRC stock today

AtriCure (ATRC) closed at $55.39 on Nov 20, up 2.37% (+$1.28), versus the S&P 500's 3.70% decline. At this level, ATRC sits in the middle of its 52-week range of $25.36 to $66.02: 16.1% below the high, set on Nov 4, 2026 and 118.4% above the low. ATRC is up 40.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 53.1%.

At 178.7x trailing earnings, AtriCure trades above the peer-group median of 26.8x. Its forward P/E of 122.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About AtriCure

Company profile

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.

Industry
Medical/Dental Instruments
CEO
Mr. Michael H. Carrel
Headquarters
Mason, OH
Employees
1,350
IPO year
2005

Financial highlights

Full financials

In fiscal 2025, AtriCure generated $534.5 million in revenue, up 14.9% from fiscal 2024, its 5th consecutive year of revenue growth. AtriCure reported a net loss of $11.4 million, compared with a loss of $44.7 million a year earlier. Gross margin was 75.0% (up from 74.7%) and operating margin -1.8%.

AtriCure annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$534.53M$465.31M$399.25M$330.38M$274.33M
Growth+14.88%+16.55%+20.84%+20.43%+32.83%
Net income$-11.45M$-44.70M$-30.44M$-46.47M$50.20M
EPS (diluted)$-0.24$-0.95$-0.66$-1.02$1.09

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$64.89+17.15%

  • Strong buy 3
  • Buy 4
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $50.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.01 vs $0.01
Surprise
-200.00%

ATRC news

All ATRC news

AtriCure peers

Health Care sector
ATRC peer companies
CompanyPrice% ChgMarket capCompare
IRTCiRhythm Holdings Inc.94.72+0.51%$3.18Bvs ATRC
PLSEPulse Biosciences Inc45.55+2.57%$3.35Bvs ATRC
UFPTUFP Technologies Inc.290.85-2.70%$2.25Bvs ATRC
NVSTEnvista Holdings Corporation22.91-1.55%$3.67Bvs ATRC
LMATLeMaitre Vascular Inc.73.61-1.67%$1.68Bvs ATRC
XRAYDENTSPLY SIRONA Inc.8.29-2.36%$1.65Bvs ATRC
INSPInspire Medical Systems Inc.55.10-2.10%$1.60Bvs ATRC
HTFLHeartflow Inc.46.69+4.62%$4.10Bvs ATRC

Indexes, lists and sector

AtriCure stock FAQ

What is AtriCure's stock price today?

ATRC last traded at $55.39 as of Nov 20, 4:00 PM EST, up 2.37% on the day. Prices are delayed at least 15 minutes.

What is ATRC's P/E ratio?

ATRC trades at a trailing P/E ratio of 178.68 and a forward P/E of 122.12, compared with a median of 26.8 for its closest peers.

Who is AtriCure's CEO?

Mr. Michael H. Carrel is the chief executive officer of AtriCure Inc., which has about 1,350 employees.

What is the ATRC 52-week high?

The 52-week high for ATRC is $66.02 and the 52-week low is $25.36. The stock is currently 16.1% below its high.

Compare ATRC